These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 26159849)

  • 1. Overexpression of SOX2 is involved in paclitaxel resistance of ovarian cancer via the PI3K/Akt pathway.
    Li Y; Chen K; Li L; Li R; Zhang J; Ren W
    Tumour Biol; 2015 Dec; 36(12):9823-8. PubMed ID: 26159849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of Tyro3 receptor tyrosine kinase leads to the acquisition of taxol resistance in ovarian cancer cells.
    Lee C
    Mol Med Rep; 2015 Jul; 12(1):1485-92. PubMed ID: 25815442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of Cathepsin L is associated with chemoresistance and invasion of epithelial ovarian cancer.
    Sui H; Shi C; Yan Z; Wu M
    Oncotarget; 2016 Jul; 7(29):45995-46001. PubMed ID: 27351223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sox2 is involved in paclitaxel resistance of the prostate cancer cell line PC-3 via the PI3K/Akt pathway.
    Li D; Zhao LN; Zheng XL; Lin P; Lin F; Li Y; Zou HF; Cui RJ; Chen H; Yu XG
    Mol Med Rep; 2014 Dec; 10(6):3169-76. PubMed ID: 25310235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Caveolin-1 mediates chemoresistance in cisplatin-resistant ovarian cancer cells by targeting apoptosis through the Notch-1/Akt/NF-κB pathway.
    Zou W; Ma X; Hua W; Chen B; Cai G
    Oncol Rep; 2015 Dec; 34(6):3256-63. PubMed ID: 26503358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
    Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
    J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upregulation of ITGBL1 predicts poor prognosis and promotes chemoresistance in ovarian cancer.
    Song J; Yang P; Lu J
    Cancer Biomark; 2020; 27(1):51-61. PubMed ID: 31683459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ERp57‑small interfering RNA silencing can enhance the sensitivity of drug‑resistant human ovarian cancer cells to paclitaxel.
    Li S; Zhao X; Chang S; Li Y; Guo M; Guan Y
    Int J Oncol; 2019 Jan; 54(1):249-260. PubMed ID: 30431082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SOX2 promotes the migration and invasion of laryngeal cancer cells by induction of MMP-2 via the PI3K/Akt/mTOR pathway.
    Yang N; Hui L; Wang Y; Yang H; Jiang X
    Oncol Rep; 2014 Jun; 31(6):2651-9. PubMed ID: 24700142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85.
    Wu D; Lu P; Mi X; Miao J
    Arch Gynecol Obstet; 2018 Mar; 297(3):699-707. PubMed ID: 29327155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Musashi-2 is a novel regulator of paclitaxel sensitivity in ovarian cancer cells.
    Lee J; An S; Choi YM; Lee J; Ahn KJ; Lee JH; Kim TJ; An IS; Bae S
    Int J Oncol; 2016 Nov; 49(5):1945-1952. PubMed ID: 27600258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of SOX2 induces cell apoptosis and G1/S arrest in Ewing's sarcoma through the PI3K/Akt pathway.
    Ren C; Ren T; Yang K; Wang S; Bao X; Zhang F; Guo W
    J Exp Clin Cancer Res; 2016 Mar; 35():44. PubMed ID: 26969300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
    Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
    Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
    Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
    Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tectorigenin sensitizes paclitaxel-resistant human ovarian cancer cells through downregulation of the Akt and NFκB pathway.
    Yang YI; Lee KT; Park HJ; Kim TJ; Choi YS; Shih IeM; Choi JH
    Carcinogenesis; 2012 Dec; 33(12):2488-98. PubMed ID: 23027625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-630 inhibitor sensitizes chemoresistant ovarian cancer to chemotherapy by enhancing apoptosis.
    Eoh KJ; Lee SH; Kim HJ; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
    Biochem Biophys Res Commun; 2018 Mar; 497(2):513-520. PubMed ID: 29452092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FOXP1 functions as an oncogene in promoting cancer stem cell-like characteristics in ovarian cancer cells.
    Choi EJ; Seo EJ; Kim DK; Lee SI; Kwon YW; Jang IH; Kim KH; Suh DS; Kim JH
    Oncotarget; 2016 Jan; 7(3):3506-19. PubMed ID: 26654944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Silencing long non-coding RNA ROR improves sensitivity of non-small-cell lung cancer to cisplatin resistance by inhibiting PI3K/Akt/mTOR signaling pathway.
    Shi H; Pu J; Zhou XL; Ning YY; Bai C
    Tumour Biol; 2017 May; 39(5):1010428317697568. PubMed ID: 28459375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphorylated PEA-15 sensitizes ovarian cancer cells to paclitaxel by impairing the microtubule-destabilizing effect of SCLIP.
    Xie X; Bartholomeusz C; Ahmed AA; Kazansky A; Diao L; Baggerly KA; Hortobagyi GN; Ueno NT
    Mol Cancer Ther; 2013 Jun; 12(6):1099-111. PubMed ID: 23543364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical implications of REST and TUBB3 in ovarian cancer and its relationship to paclitaxel resistance.
    Gao S; Zhao X; Lin B; Hu Z; Yan L; Gao J
    Tumour Biol; 2012 Oct; 33(5):1759-65. PubMed ID: 22684772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.